Unable to afford the drugs, some patients switched to compounded copies of the medication, opening up a grey market for many pharmacies and local producers, a market that regulators are trying to curb due to concerns over safety
the risks are often ignored and downplayed, but can be quite serious such as stomach paralysis and other organ damage plus a lifelong reliance on these medicines to keep weight loss maintained
Novo raised concerns about promotion of compounded alternatives, while Hims leadership emphasized physician autonomy and expanded patient access
While these interventions demonstrate efficacy in controlled settings, their real-world application faces major challenges
This study suggests that GLP-1RAs could be promising new therapeutic agents for obese asthma patients, particularly due to their impact on the expression of IL-1 modulated by nucleotide oligomerization domain-like receptor protein 3 (NLRP3) [249]